ITOC11 — 11th ImmunoTherapy of Cancer Conference

The Immunotherapy of Cancer Conference (ITOC) is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges. ITOC is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TZM), the Wolfgang Wilmanns Stiftung (WWS), the German Cancer Consortium (DKTK), the Central European Cooperative Oncology Group (CECOG), the Chinese American Hematologist and Oncologist Network (CAHON) as well as the Comprehensive Cancer Center Munich (CCCM) in Munich. The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.

Topics: ITOC 11 Scientific Committee ​ Niroshana Anandasabapathy (Weill Cornell New York, NY, United States) Michael Bergmann (Medical University Vienna, Austria) Mascha Binder​ (Universitätsspital Basel, Switzerland) Tanja D. de Gruijl (Cancer Center Amsterdam, The Netherlands) Alexander Eggermont (Cancer Center Amsterdam, The Netherlands) Ulrich Jäger (Medical University of Vienna, Austria) Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany) Volkmar Nuessler (Munich, Germany) Johanna Olweus (Institute for Cancer Research, University of Oslo, Norway) Chong-Xian Pan (Harvard Medical School, Boston, MA, United States) Pedro Romero (Translational Tumor Immunology Group, University of Lausanne, Switzerland) José Saro (CMO LCB-Novimmune, Switzerland) Stefani Spranger (Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, United States) Marion Subklewe (Ludwig-Maximilians-Universität, Munich, Germany) Eric Tartour (Hopital Européen Georges-Pompidou, Paris, France) Christoph Zielinski (Medical University of Vienna, Austria)